International Scholarly Research Notices / 2011 / Article / Tab 1

Review Article

Evaluating Smoking Cessation Interventions and Cessation Rates in Cancer Patients: A Systematic Review and Meta-Analysis

Table 1

Trial characteristics.

Author year (Ref)Study typeStudy datesSingle-center or multicenterNo. of ptsPatient characteristics
Mean age ± SD (range) (yrs)GenderMean followup (mos)Primary site of malignancy (% no. of pts)
M (no.)F (no.)

Schnoll et al. 2003 [4]RCTNRSingle7457 ± 11.438363Lung (69), Head and Neck (31)
Wakefield et al. 2004 [11]RCT2002–2008Single24654.8 ± NR1281186Lung or Head and Neck (32.2), Breast (21), Prostate (15), Lymphoma (9), Colorectal (5), Kidney, pancreas, liver (4), GU (3), Esophageal (3), Other or multiple primaries (5)
Gritz et al. 2006 [12] RCT1999–2001Single137I: 52.6 ± 13.8, U: 51.9 ± 11.585526Lung (12), Head and neck (17), Bladder (2), Breast (13), Prostate (9), Colorectal (10), Leukemia (10), Lymphoma (15), Testicle (4), Other (8)
Wewers et al. 1994 [13]RCT2000–2003Multi (4 hospitals)18457 ± 9.9155296Head and Neck: larynx (33), oropharynx/hypopharynx (30), oral cavity/other (37)
Gritz et al. 1993 [1]RCTNRMulti (10 clinics)186C: 57.8 ± 9.5, NC: 59.5 ± 9.51374912C: buccal cavity 59(52.7%), pharynx 6 (5.4%), larynx 47 (42.0%); NC: buccal cavity 58.3 (42%), pharynx 5 (6.9%), larynx 25 (34.7%)
Rothman and Greenland 1998 [15]RCTNRSingle30I: 56.4 ± 13.6, U: 53.2 ± 13.310205 weeksHeak and Neck (83.3), Breast cancer (6.7), Prostate cancer (6.7), Cervical cancer (3.3)
Greenland and Robins 1985 [16]RCTNRSingle28I: 50.2 ± 12.4,
U: 51.9 I: 50.2 ± 10.5
14161.5Gynecologic (6.21), Breast (5.18), Gastrointestinal (4.14), Thoracic (4.14), Urologic (4.14), Neurologic (4.14), Head and Neck (2.7)
Griebel et al. 1998 [17]RCTNRSingle109I: 58.7 ± 9,
U: 57.7 ± 10.1
59501 and 3Head and Neck (69), Lung (31)

F, female; I, intervention; M, male; mos, months; no., number; NR, not reported; NS, not significant; pts, patients; ref, reference; U, usual care; yrs, years, C: completers, NC: non-completers.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.